IFNA1 and Cirrhosis: According to literature data, BLV monotherapy seems to be safe and useful in patients with severe CHD, as in patients with cirrhosis and significant portal hypertension for which treatment with Peg-IFNα is contraindicated and BLV, therefore, represents the only therapeutic option.